Nonmelanoma skin cancer is a serious disease but can take a back seat to more prevalent–and often more deadly–melanoma skin cancers. Until now, there has been no champion for the development of innovative treatments in this space, especially for patients with advanced forms of nonmelanoma who have little to no treatment options left. Sanofi Genzyme and Regeneron recognized this and have partnered to research much-needed solutions for these patients. This global corporate campaign brought their dedication of both organizations to life and reinforced the shared mission that no patient with nonmelanoma should be left without treatment. Launched in May 2021, this campaign ran in parallel to communications for Libtayo, an innovative immunotherapy approved in advanced nonmelanoma skin cancers